Geistlich Pharma, North America, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$9.7M
Doctors Paid
5,645
Transactions
13,498
2024 Total
$392,659
Payment Breakdown by Category
Research$7.0M (71.5%)
Consulting$712,130 (7.3%)
Food & Beverage$648,323 (6.7%)
Travel$401,914 (4.1%)
Royalty/License$1,532 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $7.0M | 141 | 71.5% |
| Consulting Fee | $712,130 | 221 | 7.3% |
| Food and Beverage | $648,323 | 12,145 | 6.7% |
| Honoraria | $468,732 | 187 | 4.8% |
| Travel and Lodging | $401,914 | 418 | 4.1% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $279,640 | 79 | 2.9% |
| Education | $178,529 | 101 | 1.8% |
| Grant | $64,025 | 192 | 0.7% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $9,800 | 2 | 0.1% |
| Compensation for serving as faculty or as a speaker for a medical education program | $2,499 | 3 | 0.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,864 | 1 | 0.0% |
| Royalty or License | $1,532 | 6 | 0.0% |
| Gift | $58.50 | 1 | 0.0% |
| Entertainment | $15.70 | 1 | 0.0% |
Payments by Type
Research
$7.0M
141 transactions
General
$2.8M
13,357 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Phase I-II Study to Evaluate the Safety and Efficacy of PerioSept as Adjunct to SRP in Subjects With Periodontitis | $1.1M | 3 | 4 |
| PerioSept Clinical Study | $831,457 | 5 | 5 |
| Multi-center, Randomized Controlled Clinical Investigation Evaluating a Unique Advanced Wound Care Matrix versus Standard of Care in the Treatment of Diabetic Foot Ulcers | $717,658 | 0 | 5 |
| Retrospective Chart Review of Geistlich Derma Gide Wound Matrix in the Treatment of Diabetic Foot Ulcers | $714,776 | 1 | 1 |
| PERI DermaGide clinical | $526,590 | 1 | 8 |
| Evaluation of Geistlich Fibro-Gide in Comparison to CTG for the Treatment Around Implants | $298,205 | 2 | 16 |
| Evaluation of Geistlich Fibro-Gide + CAF | $259,099 | 4 | 4 |
| Evaluation of Geistlich FibroGide in comparison to CTG for the treatment around implants | $191,160 | 0 | 7 |
| Phase II Study to evaluate the safety and efficacy of PerioSept | $178,678 | 2 | 3 |
| Effects of GP-2250 in ovarian and endometrial cancers | $168,853 | 0 | 2 |
| A 4-arm randomized controlled trial of wound healing following tooth extraction and ridge preservation using DFDBA alone in particulate or fiber form, and in combinations with xenograft | $164,240 | 0 | 3 |
| Multi-center, Randomized controlled clinical investigation Evaluating a Unique Advanced Wound Care Matrix versus Standard Care in the treatment of Diabetic Foot Ulcers | $163,000 | 0 | 2 |
| A study evaluating the safety and efficiacy of soft tissue augmentation with a comprehensive-restistant colagen matrix in a non-human primate model | $123,000 | 0 | 1 |
| Phase 1/2 Trial to Evaluate the safety, tolerability, Pharmacokinetics and preliminary efficacy of GP-2250 in combination with Gemcitabine in subjects with advanced unresectable or Metastatic pancreatic Adenocarcinoma who have progressed on prior treatment with Folfirinox Chemotherapy | $108,334 | 0 | 12 |
| Prospective, randomized and controlled multi-center study to assess safety and non-inferiority effectiveness of Fibro-Gide | $100,000 | 5 | 5 |
| Clinical Trial of the efficacy of Pinhole Gum rejuvenation | $82,947 | 1 | 1 |
| A Phase I/II Study to Evaluate the Safety and Efficacy of PerioSept as Adjunct to SRP in Subjects With Periodontitis | $75,554 | 0 | 1 |
| Hard and Soft Tissue Dimensional Changes and Vascular Perfusion Around Immediately Placed Implants with or without Soft Tissue Augmentation: A 3-arm Parralles Randomized Trial | $75,000 | 0 | 2 |
| Alveolar Ridge Augmentation in Humans: Yxoss vs Titanium Mesh | $75,000 | 0 | 1 |
| GP-2250 1001 Phase 1/2 Trial to Evaluate the safety, tolerability, Pharmacokinetics and preliminary efficacy of GP-220 in combination with Gemcitabine in subjects with advanced unresectable or Metastatic pnacreatic Adenocarcinoma who have progressed on prior treatment with Folfirinox Chemotherapy | $73,218 | 0 | 2 |
| Evaluation of Geistlich Fibro-Gide + CAF in Comparison to CTG + CAF for the Treatment of Recession Defects at 6 Months | $71,476 | 0 | 2 |
| Clinical, Radiographic and Histomorphotmetric Analysis of Healing Dynamics in Human Extraction Sockets Grafted With Bio-Oss Collagen: A Prospective 3-year Post-loading Study | $64,000 | 0 | 1 |
| Mucograft Seal Study IIT | $63,601 | 1 | 1 |
| A Phase 1/2 Trial of GP-2250 in Combination With Gemcitabine in Pancreatic Adenocarcinoma After FOLFIRINOX Chemotherapy | $59,211 | 2 | 2 |
| GP-2250 1001 Phase 1/2 Trial to Evaluate the safety, tolerability, Pharmacokinetics and preliminary efficacy of GP-2250 in combination with Gemcitabine in subjects with advanced unresectable or Metastatic pnacreatic Adenocarcinoma who have progressed on prior treatment with Folfirinox Chemotherapy | $54,479 | 0 | 7 |
| Ultrasonographic echontensity analysis assessing the integration of a xenogeneic collagen matrix and its induced soft tissue phenotype modification at grafted sites following root coverage procedures | $50,000 | 1 | 2 |
| Clinical, Radiographic and Histomorphometric Analysis of Healing Dynamics in Human Extraction sockets Grafted with Bio-Oss Collagen: A prospective 3 year post-loading study | $48,000 | 0 | 1 |
| Mucograft Seal study IIT | $47,233 | 1 | 1 |
| Clarix Flo Furcation Case series Sty | $42,000 | 1 | 1 |
| Prospective, comparative assessment of alveolar preservation using Vallomix (TBA) in atraumatic extraction socket | $40,000 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Dr. Michael Mcguire, D.d.s, D.D.S | Periodontics | Houston, TX | $2.1M | $0 |
| Dr. Charles Zelen, Dpm, DPM | Foot & Ankle Surgery | Roanoke, VA | $1.3M | $0 |
| Dr. Donald Clem, D.d.s, D.D.S | Periodontics | Fullerton, CA | $193,424 | $0 |
| Dr. Othman Shibly, Dds, Ms, DDS, MS | Periodontics | Buffalo, NY | $181,602 | $0 |
| Dr. Robert Levine, Dds, Pc, DDS, PC | Periodontics | Philadelphia, PA | $151,560 | $0 |
| Mr. Tae-Ju Oh, Dds Ms, DDS MS | Periodontics | Warren, MI | $136,670 | $0 |
| Eric Scheyer, D.d.s, D.D.S | Periodontics | Houston, TX | $108,971 | $0 |
| Dr. Joseph Fiorellini, Dmd, DMD | Periodontics | Philadelphia, PA | $99,741 | $0 |
| Lorenzo Tavelli | Periodontics | Cambridge, MA | $94,812 | $0 |
| Dr. Thiago Morelli, Dds, Ms, DDS, MS | Periodontics | Raleigh, NC | $92,199 | $0 |
| Dr. Diego Velasquez-Plata, Dds, Msd, DDS, MSD | Periodontics | Fenton, MI | $91,424 | $0 |
| Dr. Richard Bauer, Dmd, Md, DMD, MD | Oral and Maxillofacial Surgery | Wexford, PA | $82,253 | $0 |
| Alan Herford, Md, Dds, MD, DDS | Oral and Maxillofacial Surgery | Colton, CA | $70,619 | $0 |
| Hector Rios, Dds, DDS | General Practice | Ann Arbor, MI | $68,713 | $0 |
| Dr. Hector Sarmiento, D.m.d., M.sc, D.M.D., M.SC | Periodontics | New York, NY | $61,137 | $0 |
| Thomas Serena, Md, MD | Surgery | Shenandoah, TX | $55,981 | $0 |
| Dr. John Chao, D.d.s, D.D.S | General Practice | Alhambra, CA | $55,084 | $0 |
| Dr. Amanda Finger Stadler, Dds, Msd, Phd, DDS, MSD, PHD | Periodontics | Chapel Hill, NC | $51,436 | $0 |
| Dr. John Gunsolley, Dds, DDS | Periodontics | Richmond, VA | $49,801 | $0 |
| Dr. Tamir Wardany, D.d.s, D.D.S | General Practice | San Francisco, CA | $48,196 | $0 |
| Dr. George Mandelaris, Dds, DDS | Periodontics | Oakbrook Terrace, IL | $42,734 | $0 |
| Dr. Philip Philip, Md Phd Frcp, MD PHD FRCP | Internal Medicine | Detroit, MI | $40,511 | $0 |
| Dr. Cristiano Susin, Dds, DDS | Periodontics | Augusta, GA | $40,330 | $0 |
| Dr. Wasik Ashraf, D.o, D.O | Orthopaedic Surgery | New Windsor, NY | $38,647 | $0 |
| Scott Froum, Dds, DDS | Periodontics | New York, NY | $34,798 | $0 |
Ad
Top Products
- GPAG No 510K $2.1M
- Derma Gide $982,871
Associated Products (27)
- GPAG No 510K $2.1M
- Derma Gide $982,871
- Bio-Gide $778,266
- DermaGide $749,359
- Derma-Gide $621,912
- Fibro Gide $597,630
- Bio-Oss $564,793
- Fibro-Gide $481,513
- MucoGraft $329,104
- Bio-Materials $325,951
- Bio Materials $236,689
- Geistlich Bio-Gide $227,771
- Bio-Oss Collagen $196,838
- Geistlich BioOss $111,855
- Geistlich FibroGide $109,000
- BioOss $92,385
- Geistlich BioGide $78,375
- Bio-Oss Canc 0.25-1, 0.25g $63,536
- Mucograft $49,292
- BioOss Collagen $31,688
- Geistlich Fibro Gide $20,000
- GEISTLICH DERMA-GIDE $19,622
- Geistlich Derma-Gide $18,761
- NCT04703738 $17,790
- Geistlich Derma Gide $16,538
- Gem 21 $12,357
- Fibrogide $12,000
Payment Categories
- Food & Beverage $648,323
- Consulting $712,130
- Travel & Lodging $401,914
- Research $7.0M
- Royalties $1,532
About Geistlich Pharma, North America, Inc.
Geistlich Pharma, North America, Inc. has made $9.7M in payments to 5,645 healthcare providers, recorded across 13,498 transactions in the CMS Open Payments database. In 2024, the company paid $392,659. The top product by payment volume is GPAG No 510K ($2.1M).
Payments were distributed across 66 medical specialties. The top specialty by payment amount is Periodontics ($4.2M to 1,513 doctors).
Payment categories include: Food & Beverage ($648,323), Consulting ($712,130), Research ($7.0M), Travel & Lodging ($401,914), Royalties ($1,532).
Geistlich Pharma, North America, Inc. is associated with 27 products in the CMS Open Payments database, including GPAG No 510K, Derma Gide, and Bio-Gide.